Verge Genomics will use digital biomarkers to assess short-term disease progression in an ALS trial testing its VRG50635 ...

The trial will explore the ALS biomarkers, including the change from baseline in levels of neurofilament light chain.

RAG-17 therapy slowed functional decline and stabilized or improved breathing in people with ALS who carry mutations in the SOD1 gene.

“We are thrilled to be the first company to evaluate multiple digital clinical biomarker endpoints in an ALS therapeutic trial to gauge short-term disease progression across key functional ...

As part of cost-cutting measures across the federal government, the Trump administration last month instituted a new National ...

PrimeC has demonstrated promising results in the 18-month Phase 2b trial, with data highlighting its potential as a disease-modifying therapy for ALS. The trial revealed a marked reduction in ALS ...

Overnight, and to my surprise, I became the face of research at Harvard. But my daughter’s text was not the only surprise I ...

Substantial reduction in key biomarker: Significant reductions in ... The average decrease in the ALS Functional Rating Scale-Revised (ALSFRS-R) score was 2.17 points over the study period ...

A Series in The Lancet Neurology provides state-of-the-art reviews covering clinical and scientific evidence on the four most common genetic subtypes of amyotrophic lateral sclerosis (ALS), caused by ...